InspireMD, Inc.: insider trades · United States · SEC (Form 4)

About InspireMD, Inc.

InspireMD, Inc. (Nasdaq: NSPR) is a U.S.-based medical device company focused on stroke prevention through carotid stenting solutions. The company is headquartered in Miami, Florida, with significant operations in Tel Aviv, Israel. It was founded in 2005 and trades on the Nasdaq Capital Market. Its business model centers on developing, commercializing, and extending a proprietary embolic protection platform aimed at improving clinical outcomes in vascular interventions. ([investors.inspiremd.com](https://investors.inspiremd.com/ir-resources/investor-faqs?utm_source=openai)) The company’s core technology is MicroNet™, a proprietary mesh designed to reduce plaque prolapse and embolic debris during carotid artery treatment. InspireMD’s flagship product is CGuard Prime, a carotid stent system developed for stroke prevention, and management has also highlighted broader potential applications of the platform beyond carotid disease. Historically, InspireMD has commercialized CGuard and MGuard Prime in international markets, building clinical experience and regulatory familiarity outside the United States. ([inspiremd.com](https://inspiremd.com/about/?utm_source=openai)) From a competitive standpoint, InspireMD operates in a highly specialized niche against much larger multinational medical device companies with far greater manufacturing, commercial, and regulatory resources. The company’s differentiation is therefore based on technology, clinical evidence, and a focused position in carotid embolic protection. That specialization can be attractive if physician adoption and reimbursement support scale-up, but it also leaves the stock exposed to execution, funding, and commercialization risk. ([inspiremd.com](https://inspiremd.com/news/inspiremd-announces-establishment-of-global-headquarters-in-miami-florida-to-support-anticipated-u-s-launch-and-commercialization-of-the-cguard-prime-carotid-stent-system/?utm_source=openai)) The most important recent development is the FDA approval announced on June 24, 2025 for the CGuard Prime Carotid Stent System, a major milestone that supports U.S. commercialization. InspireMD had already established a global headquarters in Miami in October 2024 to prepare for the anticipated U.S. launch. The company’s 2024 and 2025 financial updates also point to rising investment in U.S. commercial infrastructure, signaling a transition from a largely international commercial footprint toward a more fully built domestic presence. ([investors.inspiremd.com](https://investors.inspiremd.com/news-releases/news-release-details/inspiremd-announces-fda-approval-cguardr-prime-carotid-stent?utm_source=openai)) For French-speaking investors, InspireMD is a U.S.-listed healthcare name with meaningful regulatory and commercial optionality, but one that still depends on successful U.S. launch execution, geographic expansion, and the conversion of clinical data into durable revenue growth. ([investors.inspiremd.com](https://investors.inspiremd.com/ir-resources/investor-faqs?utm_source=openai))